---
layout: default
title: Publications
permalink: /publications/
---

# Publications

A curated list of publications, preprints, and conference abstracts from the Bose Lab.[web:16]

---

## Selected publications

- Arora R, Cao C, Kumar M, Sinha S, Chanda A, McNeil R, Samuel D, Matthews TW, Nakoneshny SC, Hart RD, Chandarana SP, Dort JC, Hyrcza MD, Gallo M, Bonni S, **Bose P**, et al. *Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response.* Nature Communications 14 (1), 5029 (2023).[web:80]

- Mirzaei R, McNeil R, D'Mello C, Wong B, Sarkar S, Visser F, Poon C, **Bose P**, Yong VW. *Spatial single-cell profiling identifies protein kinase Cδ-expressing microglia with anti-tumor function in glioblastoma.* iScience (2025).[web:30]

- Ghahremanifard P, An J, Chanda A, Chan AMY, Nakoneshny SC, Matthews TW, Chandarana SP, Hart RD, Hyrcza MD, Dort JC, Bonni S, **Bose P**. *PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma.* Cancers 17 (17), 2905 (2025).[web:39][web:41]

- De Boeck A, Ahn BY, D’Mello C, Lun X, Menon SV, Alshehri MM, … **Bose P**, et al. *Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression.* Nature Communications 11 (1), 4997 (2020).[web:76]

---

## Publications (2025–2020)

### 2025

- Mirzaei R, McNeil R, D'Mello C, Wong B, Sarkar S, Visser F, Poon C, **Bose P**, Yong VW. *Spatial single-cell profiling identifies protein kinase Cδ-expressing microglia with anti-tumor function in glioblastoma.* iScience (2025).[web:30]

- Ghahremanifard P, An J, Chanda A, Chan AMY, Nakoneshny SC, Matthews TW, Chandarana SP, Hart RD, Hyrcza MD, Dort JC, Bonni S, **Bose P**. *PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma.* Cancers 17 (17), 2905 (2025).[web:39][web:41]

- Gagnon R, Kish EK, Cook S, Takemura K, Cheng BYC, Bressler K, Heng DYC, Alimohamed N, Ruether D, Lee-Ying RM, **Bose P**, Kolinsky MP, Vasquez C, Samuel D, Lewis J, Faridi R, Borkar M, Fairey A, Bismar T, Yip S. *Real-world clinical outcomes and prognostic factors in neuroendocrine prostate cancer.* Clinical Genitourinary Cancer 23 (1), 102274 (2025).[web:27]

- Jette NR, Radhamani S, Ye R, Yu Y, Arthur G, Goutam S, Bismar TA, … **Bose P**, et al. *Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.* British Journal of Cancer 122 (12), 1872 (2020, correction listed in 2025 block in Scholar list).[web:57]

(*Continue filling 2025 full articles exactly as listed once you decide which non-oncology items to keep.*)

### 2024

- Rajwani J, Vishnevskiy D, Turk M, Naumenko V, Gafuik C, Kim DS, … **Bose P**, et al. *VSV∆M51 drives CD8+ T cell-mediated tumour regression through infection of both cancer and non-cancer cells.* Nature Communications 15 (1), 9933 (2024).[web:50]

- Patysheva MR, Kolegova ES, Khozyainova AA, Prostakishina EA, … **Bose P**, et al. *Revealing molecular mechanisms of early-onset tongue cancer by spatial transcriptomics.* Scientific Reports 14 (1), 26255 (2024).[web:26]

- Sarkar S, Chanda A, Khanolkar RA, Lambie M, Ailles L, Bratman SV, **Bose P**, et al. *Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.* Biomedicines 12 (3), 503 (2024).[web:54]

### 2023

- Arora R, Cao C, Kumar M, Sinha S, Chanda A, McNeil R, Samuel D, Matthews TW, Nakoneshny SC, Hart RD, Chandarana SP, Dort JC, Hyrcza MD, Gallo M, Bonni S, **Bose P**, et al. *Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response.* Nature Communications 14 (1), 5029 (2023).[web:80]

- Gupta M, Kannappan SN, Jain M, Douglass D, Shah R, **Bose P**, et al. *Development and validation of a 21-gene prognostic signature in neuroblastoma.* Scientific Reports 13 (1), 12526 (2023).[web:68]

- Bourhill T, Rohani L, Kumar M, **Bose P**, Rancourt D, Johnston RN. *Modulation of reoviral cytolysis (II): cellular stemness.* Viruses 15 (7), 1473 (2023).[web:68]

- Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny SC, … **Bose P**, et al. *NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma.* Cancer Gene Therapy 30 (5), 752–765 (2023).[web:71]

- Kumar M, Meode M, Blough M, Cairncross G, **Bose P**. *PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas.* NPJ Genomic Medicine 8 (1), 6 (2023).[web:73]

- Mirzaei R, D'Mello C, Liu M, Nikolic A, Kumar M, Visser F, **Bose P**, Gallo M, et al. *Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells.* Cancer Research 83 (10), 1725–1741 (2023).[web:21]

### 2022

- Zeng PYF, Cecchini MJ, Barrett JW, Shammas-Toma M, De Cecco L, Serafini M, … **Bose P**, et al. *Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.* EBioMedicine 86 (2022).[web:65]

- Standing S, Tran S, Murguia-Favela L, Kovalchuk O, **Bose P**, Narendran A. *Identification of Altered Primary Immunodeficiency-Associated Genes and Their Implications in Pediatric Cancers.* Cancers 14 (23), 5942 (2022).[web:57]

- Bose P, Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny SC, et al. *NCBP2 and TFRC are Novel Prognostic Biomarkers in Oral Squamous Cell Carcinoma.* (Cancers / Cancer Gene Therapy listing, 2022 online-first entry).[web:71]

### 2021–2020 (journal articles only)

- Mirzaei R, Gordon A, Zemp FJ, Kumar M, Sarkar S, Luchman HA, … **Bose P**, et al. *PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway.* Science Advances 7 (45), eabh2148 (2021).[web:76]

- Dzikowski L, Mirzaei R, Sarkar S, Kumar M, **Bose P**, Bellail A, Hao C, Yong VW, … et al. *Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor‐initiating cells.* Brain Pathology 31 (5), e12947 (2021).[web:76]

- Hildebrand KM, Singla AK, McNeil R, Marritt KL, Hildebrand KN, Zemp F, **Bose P**, et al. *The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.* PLOS ONE 16 (7), e0253864 (2021).[web:76]

- Ghahremanifard P, Chanda A, Bonni S, **Bose P**. *TGF-β mediated immune evasion in cancer—spotlight on cancer-associated fibroblasts.* Cancers 12 (12), 3650 (2020).[web:74]

- Jette NR, Radhamani S, Ye R, Yu Y, Arthur G, Goutam S, Bismar TA, Yip S, Kolinsky M, **Bose P**, Booth CM, et al. *ATM-deficient cancers provide new opportunities for precision oncology.* Cancers 12 (3), 687 (2020).[web:57]

- Sarkar S, Li Y, Mirzaei R, Rawji KS, Poon CC, Wang J, Kumar M, **Bose P**, Yong VW. *Demeclocycline reduces the growth of human brain tumor-initiating cells: direct activity and through monocytes.* Frontiers in Immunology 11, 272 (2020).[web:76]

- Obaid H, Kannappan S, Gupta M, Ruan Y, Zhang C, **Bose P**, Narendran A. *In vitro investigation demonstrates IGFR/VEGFR receptor cross talk and potential of combined inhibition in pediatric central nervous system atypical teratoid rhabdoid tumors.* Current Cancer Drug Targets 20 (4), 295–305 (2020).[web:57]

- Sarkar S, Yang R, Mirzaei R, Rawji K, Poon C, Mishra MK, Zemp FJ, **Bose P**, Yong VW. *Control of brain tumor growth by reactivating myeloid cells with niacin.* Science Translational Medicine 12 (537), eaay9924 (2020).[web:76]

- ### 2019

- Jette N, Radhamani S, Arthur G, Ye R, Goutam S, Bolyos A, Petersen LF, **Bose P**, et al. *Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.* British Journal of Cancer 121 (7), 600–610 (2019).[web:16]

- Shen Y, Grisdale CJ, Islam SA, **Bose P**, Lever J, Zhao EY, Grinshtein N, … et al. *Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.* Proceedings of the National Academy of Sciences 116 (38), 19098–19108 (2019).[web:16]

### 2018

- Chakravarthy A, Khan L, Bensler NP, **Bose P**, De Carvalho DD. *TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure.* Nature Communications 9 (1), 4692 (2018).[web:16]

- Sarkar S, Poon CC, Mirzaei R, Rawji KS, Hader W, **Bose P**, Kelly J, Yong VW. *Microglia induces Gas1 expression in human brain tumor-initiating cells to reduce tumorigenecity.* Scientific Reports 8 (1), 15286 (2018).[web:16]

- Mirzaei R, Sarkar S, Dzikowski L, Rawji KS, Khan L, Faissner A, **Bose P**, Yong VW. *Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.* OncoImmunology 7 (10), e1478647 (2018).[web:16]

### 2017

- Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, … **Bose P**, et al. *Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer.* Clinical Cancer Research 23 (24), 7521–7530 (2017).[web:16]

- Hobbs AJ, Brockton NT, Matthews TW, Chandarana SP, **Bose P**, et al. *Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: a population-based study.* Head & Neck 39 (11), 2187–2199 (2017).[web:16]

- Brockton NT, Lohavanichbutr P, Enwere EK, Upton MP, Kornaga EN, **Bose P**, et al. *Impact of tumoral carbonic anhydrase IX and Ki‑67 expression on survival in oral squamous cell carcinoma patients.* Oncology Letters 14 (5), 5434–5442 (2017).[web:16]


---

## Preprints & abstracts (2020–2025)

- Mirzaei R, McNeil R, D’Mello C, Wong B, Sarkar S, Visser F, Poon C, **Bose P**, Yong VW. *Spatially resolved single-cell analysis uncovers protein kinase Cδ-expressing microglia with anti-tumor activity in glioblastoma.* bioRxiv, 2023.12.04.570023 (2023).[web:31]

- Marret G, An J, Penny L, Wang B, Sayad A, Spreafico A, Sanz Garcia E, Hansen AR, Chow H, Bratman S, **Bose P**, Siu LL. *Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC).* Journal of Clinical Oncology 43 (16_suppl), 6045–6045 (2025).[web:45]

- Alimohamed NS, Gibson AW, Dean ML, Xu TJ, Murali M, Banjaw RK, Basappa NS, Bismar TA, Dehar N, Karim S, Kolinsky MP, Heng DYC, Lee-Ying RM, Navani V, North SA, Ruether JD, Taleb A, Osborne BJW, **Bose P**, Yip S. *Understanding diversity and disparities in a real-world locally advanced/metastatic urothelial carcinoma (la/mUC): Clinical characteristics, genomic landscape, and self …* Journal of Clinical Oncology 43 (5_suppl), 669–669 (2025).[web:45]

- Yip SM, Gibson AJ, Takemura K, Gagnon R, Vo K, Kolinsky M, Heng DYC, Ruether JD, North S, Alimohamed N, Karim S, Kinnaird A, Tucker T, Xu TJ, Dean ML, Murali M, Selvarajah S, Chi KN, **Bose P**, El Hallani SE. *2451P Real-world (RW) genomic landscape, PARP inhibitor (PARPi) treatment (tx) patterns and adverse events (AE) in advanced prostate cancer (PCa): the national CanaDNA Study.* Annals of Oncology 36, S1330 (2025).[web:51]

- **Bose P**, Gibson A, Dean M, Xu T, Murali M, Kolinsky M, North SA, Heng DYC, Ruether JD, Karim S, Navani V, Lee-Ying R, Osborne B, Bismar TA, Fahidi R, Sharma S, Alam S, Khan F, Alimohamed N, Yip SM. *76eP Clinical-grade comprehensive genomic profiling (CGP) of urothelial carcinoma (UC).* ESMO Open 10 (2025).[web:51]

- Arora R, Cao C, Kumar M, Chanda A, Samuel D, Matthews W, Nakoneshny S, **Bose P**, et al. *Spatial transcriptomics unravels novel signaling patterns at the leading edge of oral squamous cell carcinoma.* Journal of Clinical Oncology 40 (16_suppl), e18043–e18043 (2022).[web:64]

- Zeng PYF, Cecchini MJ, Barrett JW, Shammas-Toma M, De Cecco L, Serafini M, Tabola R, De Petris L, **Bose P**, Bratman SV. *A Clinically Translatable Immune-based Classification of HPV-associated Head and Neck Cancer with Implications for Biomarker-Driven Treatment Deintensification and Immunotherapy.* medRxiv, 2022.02.26.22271531 (2022).[web:65]

- Bolyos A, **Bose P**. *Abstract A07: Improved prognosis of HPV-positive oropharyngeal cancers is associated with a suppression of TGF-β-mediated immune evasion.* Clinical Cancer Research 26 (12_Supplement_2), A07–A07 (2020).[web:74]

- Bolyos A, **Bose P**. *Improved prognosis of HPV-positive oropharyngeal cancers is associated with a suppression of TGF-beta-mediated immune evasion.* Clinical Cancer Research 26 (12), 33–33 (2020).[web:74]

- ### Older preprints & abstracts

- Jette N, Radhamani S, Arthur G, Ye R, Goutam S, Boylos A, Petersen L, **Bose P**, et al. *P1.14-41 The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells.* Journal of Thoracic Oncology 14 (10), S570–S571 (2019).[web:16]

- Bose P, Boylos A, Petersen L, Kovalchuk O, Kovalchuk I, Dean M, Itani D, … et al. *MA04.10 Development and Validation of a Gene Expression-Based Prognostic Signature in Early-Stage Squamous Cell Carcinoma of the Lung.* Journal of Thoracic Oncology 14 (10), S263–S264 (2019).[web:16]

- Chakravarthy A, Khan L, Bensler NP, **Bose P**, De Carvalho DDD. *Abstract LB-362: A TGF-beta linked ECM-dysregulation programme in CAFs drives immune evasion and immunotherapy resistance.* Cancer Research 78 (13_Supplement), LB-362–LB-362 (2018).[web:16]

- Chakravarthy A, Khan L, Bensler NP, **Bose P**, De Carvalho DDD. *Immune evasion and immunotherapy resistance via TGF-beta activation of extracellular matrix genes in cancer associated fibroblasts.* bioRxiv 265884 (2018).[web:16]

- Goepfert RP, Fuller CD, Gunn GB, Hanna EY, Lewin JS, Zaveri JS, … **Bose P**, et al. *[JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK – article title per journal record].* 2017 entry as listed in Scholar (keep as-is or replace with full title once you have it from the journal site).[web:16]

